PCM
TGTX icon

Prelude Capital Management’s TG Therapeutics TGTX Stock Holding History

Prelude Capital Management’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-20,800
Closed -$246K – 1460
2022
Q4 		$246K Sell
20,800
-100
-0.5% -$726 0.01% 884
2022
Q3 		$10K Hold
20,900
– – ﹤0.01% 1316
2022
Q2 		$89K Sell
20,900
-200
-0.9% -$1.25K ﹤0.01% 1432
2022
Q1 		$201K Sell
21,100
-1,700
-7% -$19.7K 0.01% 1267
2021
Q4 		$433K Buy
22,800
+5,000
+28% +$130K 0.01% 1103
2021
Q3 		$592K Buy
+17,800
New +$551K 0.02% 812
2020
Q3 		– Sell
-3,000
Closed -$58K – 2337
2020
Q2 		$58K Buy
+3,000
New +$48.3K ﹤0.01% 1125
2020
Q1 		– Sell
-20,500
Closed -$228K – 2016
2019
Q4 		$228K Buy
20,500
+20,000
+4,000% +$152K 0.01% 815
2019
Q3 		$3K Sell
500
-400
-44% -$2.79K ﹤0.01% 1604
2019
Q2 		$8K Sell
900
-100
-10% -$756 ﹤0.01% 1441
2019
Q1 		$8K Buy
+1,000
New +$5.41K ﹤0.01% 1548
2014
Q4 		– Sell
-9,800
Closed -$105K – 2146
2014
Q3 		$105K Sell
9,800
-6,700
-41% -$62.1K 0.01% 1064
2014
Q2 		$155K Buy
16,500
+4,300
+35% +$27.5K 0.02% 850
2014
Q1 		$84K Buy
+12,200
New +$72.2K 0.01% 1091

Other funds holding TGTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Prelude Capital Management's TGTX Position: Q4 2024 in Review

Prelude Capital Management sold out of TG Therapeutics (TGTX) in Q4 2024, closing a stake of 57,497 shares — an estimated $1.34M sold.

Prelude Capital Management first reported a position in TGTX in Q1 2014 and held it in 18 quarters. The position peaked at $1.34M in Q3 2024. 331 funds tracked by Wall St. Rank hold TGTX as of Q4 2024.

  • Prelude Capital Management reported no remaining TG Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Prelude Capital Management sold 57,497 TG Therapeutics shares in Q4 2024, an estimated $1.34M.
  • Prelude Capital Management first reported a position in TG Therapeutics in Q1 2014 and held it in 18 quarters.
  • Prelude Capital Management's TG Therapeutics position peaked at $1.34M in Q3 2024.
  • 331 funds tracked by Wall St. Rank held TG Therapeutics as of Q4 2024.

Based on Prelude Capital Management's 13F filing for Q4 2024, filed 14 Feb 2025.